However, the mean discomfort index was considerably less in individuals acquiring alfuzosin . Both groups were similar in days off of work and in the ability to engage in sexual activity. Less pain with sexual activity was reported in the alfuzosin group and this was significant. The mean global quality-of-life rating with the stent in situ was equivalent in both groups of patients. Related StoriesDAPT Study displays dual antiplatelet therapy decreases bleeding-related mortalityExtending bivalirudin treatment after PCI will not improve ischemic and bleeding outcomesLEADERS Free of charge clinical trial demonstrates superior security, efficacy for BioFreedom weighed against bare-metal stentIn overview, the keeping indwelling ureteral stents has become routine in the administration of a number of urinary tract diseases.The LAP-BAND program, one of the many fascinating initiatives we have under way for 2010, is an important component of our ongoing dedication to bariatrics. Source COVIDIEN.
Adolor initiates second ADL5945 Phase 2 research in opioid-induced constipation Adolor Company today announced that it’s initiating a second Phase 2 study of ADL5945 in chronic non-cancer pain individuals experiencing opioid-induced constipation .10 mg and 0.25 mg) each administered twice daily in sufferers with OIC.